3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
10
Carcinoma, Non-Small-Cell Lung
4
Triple Negative Breast Neoplasms
2
Recurrence
2
Melanoma
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myelomonocytic, Acute
2
Leukemia, Myeloid, Acute
2
Carcinoma, Renal Cell
2
Uveal Melanoma
1
Urinary Bladder Neoplasms
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Mammary Neoplasms, Animal
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Promyelocytic, Acute
1
Leukemia, Monocytic, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Erythroblastic, Acute
1
Hodgkin Disease
1
Congenital Abnormalities
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Breast Neoplasms, Male
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
exemestane
1
entinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Mammary Neoplasms, Animal
×
entinostat
×
Clear all
NCT00676663
2022-05-11
ENCORE301
Syndax Pharmaceuticals
Phase 2
Completed
130 enrolled
18 charts